SCHEDULE: Venture Funds Boost Stake in Shoulder Innovations

U.S. Venture Partners and affiliates disclose significant passive beneficial ownership in Shoulder Innovations, Inc., with Casey M. Tansey holding a 13.3% stake.

Summary

• U.S. Venture Partners XII, L.P. (USVP XII) reported beneficial ownership of 1,686,403 shares, representing 8.2% of Shoulder Innovations, Inc.'s common stock.
• Presidio Management Group XII, L.L.C. (PMG XII), the general partner of USVP XII, reported beneficial ownership of 2,693,121 shares, or 13.1% of the common stock.
• Casey M. Tansey, a managing partner of PMG XII and a board member of Shoulder Innovations, Inc., reported beneficial ownership of 2,740,787 shares, or 13.3% of the common stock.
• The reported ownership is based on 20,601,684 shares outstanding as of November 5, 2025.
• The shares beneficially owned by PMG XII include holdings from USVP XII, U.S. Venture Partners XII-A, L.P., and U.S. Venture Partners Select Fund I, L.P.
• The reporting persons expressly disclaim 'group' status for purposes of this Schedule 13G and disclaim beneficial ownership beyond their pecuniary interest.

Sentiment

Score: 7

Explanation: The filing indicates continued strong institutional backing from a reputable venture capital firm, with a board member holding a significant stake. This suggests confidence in the company's prospects, although it's a factual ownership disclosure rather than a performance report.

Positives

• Continued significant investment from established venture capital firms (U.S. Venture Partners) indicates confidence in Shoulder Innovations, Inc.'s long-term potential.
• The presence of Casey M. Tansey, a managing partner of the venture group, on the Issuer's board of directors suggests active oversight and strategic alignment.

Risks

• Concentrated ownership by venture capital funds could lead to significant influence over corporate decisions, potentially prioritizing fund objectives over broader shareholder interests.
• The disclaimer of 'group' status, while legally compliant, highlights the potential for coordinated action among the reporting persons without formal group designation.

Future Outlook

This Schedule 13G filing does not contain specific forward-looking statements or guidance regarding the Issuer's future performance or strategic direction.

Management Comments

• Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein.
• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.

Industry Context

The continued significant stake held by U.S. Venture Partners, a prominent venture capital firm, suggests ongoing investor confidence in the medical device and orthopedics sector, particularly in companies focused on innovative surgical solutions like Shoulder Innovations. This type of institutional backing is common for growth-stage companies in specialized healthcare markets.

Comparison to Industry Standards

• The beneficial ownership percentages (8.2% to 13.3%) are substantial for a single institutional investor or related group, indicating a strong conviction in Shoulder Innovations, Inc.
• Venture capital firms like U.S. Venture Partners typically invest in high-growth potential companies, often in the technology and healthcare sectors, aligning with Shoulder Innovations' focus on orthopedic innovation.
• The presence of a venture partner (Casey M. Tansey) on the company's board is a standard practice for venture-backed companies, providing strategic guidance and oversight.

Corporate Governance

Related Party Transactions

• Casey M. Tansey, a member of Shoulder Innovations, Inc.'s board of directors, is also a managing partner of Presidio Management Group XII, L.L.C., which beneficially owns a significant stake in the company.
• Dr. Jonathan Root, also a member of the Issuer's board, is a managing member of Presidio Management Group XII, L.L.C., further linking the board and the venture capital investor.

Stakeholder Impact

• Shareholders: The significant and continued investment by U.S. Venture Partners may be viewed positively, signaling institutional confidence. However, concentrated ownership could also mean less influence for smaller shareholders.
• Management: The presence of venture capital representatives on the board implies close oversight and strategic direction from major investors.

Next Steps

• Shoulder Innovations, Inc. will continue to operate under the strategic guidance influenced by its board, including Casey M. Tansey.
• U.S. Venture Partners and its affiliates will maintain their oversight and potential influence as significant shareholders.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses beneficial ownership by U.S. Venture Partners and its affiliates, including a board member. It indicates continued institutional confidence in Shoulder Innovations, Inc. The filing itself does not provide new financial performance data or strategic shifts that would warrant a 'buy' or 'sell' recommendation. The substantial and stable ownership by a reputable venture capital firm, with direct board representation, suggests a stable long-term investment thesis, making 'hold' an appropriate recommendation for existing investors. New investors would need more comprehensive financial and operational data to make an informed decision.

Keywords

Shoulder Innovations, USVP, U.S. Venture Partners, Schedule 13G, Beneficial Ownership, Venture Capital, Medical Devices, Orthopedics, Institutional Investor, SEC Filing